Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety

Sanford H RothArizona Research and Education, Arthritis Laboratory, Arizona State University, Phoenix, AZ, USAAbstract: Chronic oral or systemic nonselective nonsteroidal anti-inflammatory drug (NSAID) therapy, ubiquitously used by physicians to treat osteoarthritis-associated pain, is associated wi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Roth SH
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	NSAIDs osteoarthritis topical administration synovial fluid peptic ulcer helicobacter pylori Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/dfb181048b264eedacbeeaa3e57b234d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dfb181048b264eedacbeeaa3e57b234d
record_format	dspace
spelling	oai:doaj.org-article:dfb181048b264eedacbeeaa3e57b234d2021-12-02T08:37:02ZNonsteroidal anti-inflammatory drug gastropathy: new avenues for safety1178-1998https://doaj.org/article/dfb181048b264eedacbeeaa3e57b234d2011-05-01T00:00:00Zhttps://www.dovepress.com/nonsteroidal-anti-inflammatory-drug-gastropathy-new-avenues-for-safety-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Sanford H RothArizona Research and Education, Arthritis Laboratory, Arizona State University, Phoenix, AZ, USAAbstract: Chronic oral or systemic nonselective nonsteroidal anti-inflammatory drug (NSAID) therapy, ubiquitously used by physicians to treat osteoarthritis-associated pain, is associated with a wide range of symptomatic adverse events, the most frequent and serious of which is gastropathy. Although cardiovascular and renal problems are a very real concern, they are significantly less frequent. These complications can be life-threatening in at-risk populations such as older adults, who are common users of long-term oral systemic NSAID therapy. Topical NSAID formulations deliver effective doses of analgesics directly to the affected joints, thereby limiting systemic exposure and potentially the risk of systemic adverse events, such as gastropathy and serious cardiovascular events. There are currently two topical NSAIDs approved by the US Food and Drug Administration for osteoarthritis-associated pain, as well as for the signs and symptoms of osteoarthritis. This review discusses the relative safety, and the gastrointestinal, cardiovascular, and renal risks of chronic oral or systemic NSAID therapy and topical NSAID formulations in patients with osteoarthritis.Keywords: NSAIDs, osteoarthritis, topical administration, synovial fluid, peptic ulcer, Helicobacter pyloriRoth SHDove Medical PressarticleNSAIDsosteoarthritistopical administrationsynovial fluidpeptic ulcerhelicobacter pyloriGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 6, Pp 125-131 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	NSAIDs osteoarthritis topical administration synovial fluid peptic ulcer helicobacter pylori Geriatrics RC952-954.6
spellingShingle	NSAIDs osteoarthritis topical administration synovial fluid peptic ulcer helicobacter pylori Geriatrics RC952-954.6 Roth SH Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety
description	Sanford H RothArizona Research and Education, Arthritis Laboratory, Arizona State University, Phoenix, AZ, USAAbstract: Chronic oral or systemic nonselective nonsteroidal anti-inflammatory drug (NSAID) therapy, ubiquitously used by physicians to treat osteoarthritis-associated pain, is associated with a wide range of symptomatic adverse events, the most frequent and serious of which is gastropathy. Although cardiovascular and renal problems are a very real concern, they are significantly less frequent. These complications can be life-threatening in at-risk populations such as older adults, who are common users of long-term oral systemic NSAID therapy. Topical NSAID formulations deliver effective doses of analgesics directly to the affected joints, thereby limiting systemic exposure and potentially the risk of systemic adverse events, such as gastropathy and serious cardiovascular events. There are currently two topical NSAIDs approved by the US Food and Drug Administration for osteoarthritis-associated pain, as well as for the signs and symptoms of osteoarthritis. This review discusses the relative safety, and the gastrointestinal, cardiovascular, and renal risks of chronic oral or systemic NSAID therapy and topical NSAID formulations in patients with osteoarthritis.Keywords: NSAIDs, osteoarthritis, topical administration, synovial fluid, peptic ulcer, Helicobacter pylori
format	article
author	Roth SH
author_facet	Roth SH
author_sort	Roth SH
title	Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety
title_short	Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety
title_full	Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety
title_fullStr	Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety
title_full_unstemmed	Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety
title_sort	nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/dfb181048b264eedacbeeaa3e57b234d
work_keys_str_mv	AT rothsh nonsteroidalantiinflammatorydruggastropathynewavenuesforsafety
_version_	1718398460162473984

Nonsteroidal anti-inflammatory drug gastropathy: new avenues for safety

Ejemplares similares